- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Psychedelics For The Treatment Of Depression: Focus On 5HT-2A

Virtual Event – Psychedelics For The Treatment Of Depression: Focus On 5HT-2A
The presenters will discuss the history of psychedelics in therapeutic approaches with a primary focus on psilocybin. They will also review the neurobiology of psychedelics and the role of 5-HT2A receptors, review the results of recently published findings, and discuss the challenges associated with psychedelic-assisted therapies.
Featuring
-
Philip G. Janicak, MD
Adjunct Professor and Consultant to the Therapeutic Neuromodulation Program in the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine and a Distinguished Life Fellow in the American Psychiatric Association
-
Rachel Self, PhD, MS (OPDC)
Medical Science Director, Neuroscience Field Medical Affairs
Philip G. Janicak, MD is a consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. Rachel Self, PhD, MS is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.rn
Related Events
Register
This event registration is closed.